St. John's , Canada Clinical Trials

A listing of St. John's , Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 66 clinical trials
A Study to Assess the Efficacy Safety and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

The purpose of this study is to demonstrate the clinical efficacy of rozanolixizumab in maintenance treatment and assess safety and tolerability of rozanolixizumab in adult study participants with primary immune thrombocytopenia (ITP).

Tp0006 50384
 (1130.5 away) Contact site
  • 15 views
  • 11 Jul, 2021
  • +49 other locations
Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description

Galderma Investigational Site 8000
 (0.5 away) Contact site
  • 21 views
  • 16 Jul, 2021
  • +470 other locations
Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will assess how safe and effective risankizumab is compared to apremilast in adult participants with moderate plaque psoriasis. Adverse events and change in disease symptoms will be monitored. …

apremilast
systemic therapy
risankizumab
plaque psoriasis
arthritis
Karma Clinical Trials /ID# 230339
 (3.5 away) Contact site
  • 0 views
  • 25 Jul, 2021
  • +61 other locations
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

The main purpose of the study is to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with topical treatments.

Galderma Investigational Site
 (0.5 away) Contact site
  • 95 views
  • 16 Jul, 2021
  • +458 other locations
Pomalidomide in Combination With Low-dose Dexamethasone or Pomalidomide in Combination With Low-dose Dexamethasone and Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Following Lenalidomide-based Therapy in the First or Second Line Setting

This trial will evaluate the efficacy and safety of combination of pomalidomide (POM) and low-dose dexamethasone (LD-Dex) (Cohort A) or the combination of pomalidomide (POM) , daratumumab (DARA) and low-dose dexamethasone (LD-Dex) (Cohort B) in subjects with relapsed or refractory multiple myeloma who have received a first or second line …

bone marrow procedure
vasectomy
refractory multiple myeloma
measurable disease
daratumumab
Health Sciences Center
 (1.6 away) Contact site
  • 79 views
  • 24 Jan, 2021
  • +47 other locations
Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human) Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)

This is a multi-center, randomized, placebo-controlled, double blind clinical study to assess the efficacy and safety of two separate dose regimens of Alpha-1 MP versus placebo for 156 weeks (i.e., 3 years) using computed tomography (CT) of the lungs as the main measure of efficacy. The two Alpha-1 MP doses …

Health Sciences Centre
 (1.6 away) Contact site
  • 695 views
  • 02 Jun, 2021
  • +70 other locations
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis Post Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis

This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) therapy in patients with MF and severe thrombocytopenia (platelet count <50,000/L). Approximately 348 patients in total will be enrolled, randomized 2:1 to either pacritinib (approximately 232 patients) or …

thrombocytosis
pacritinib
direct bilirubin
blood blast count
ct scan
Eastern Regional Health Authority
 (1.6 away) Contact site
  • 506 views
  • 19 Jul, 2021
  • +177 other locations
Selinexor and Backbone Treatments of Multiple Myeloma Patients

This study will independently assess the efficacy and safety of 10 combination therapies in 11 arms, in dose-escalation/-evaluation and expansion phases, for the treatment of patients with relapsed/refractory multiple myeloma (RRMM) and newly diagnosed multiple myeloma (NDMM). The combinations to be evaluated are: Arm 1: Selinexor + dexamethasone + pomalidomide …

immunomodulatory imide drug
measurable disease
lenalidomide
monoclonal antibodies
line of therapy
Memorial Hospital of Newfoundland
 (1.6 away) Contact site
  • 50 views
  • 07 May, 2021
  • +23 other locations
Randomized Placebo-controlled Trial of FCM as Treatment for Heart Failure With Iron Deficiency

The primary objective of this study is to determine the efficacy and safety of iron therapy using intravenous (IV) ferric carboxymaltose (FCM), relative to placebo in the treatment of participants in heart failure with a reduced ejection fraction and with iron deficiency

ejection fraction
cardiac resynchronization therapy
iron
nesiritide
natriuretic peptide
Health Sciences Centre
 (1.6 away) Contact site
  • 5316 views
  • 22 Jul, 2021
  • +365 other locations
Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction

This study will assess whether an implantable defibrillator will increase the likelihood of survival in patients who have had a heart attack in the prior 5 years, have abnormal test results from a 24 hour heart monitor, and who have low normal heart function.

coronary angioplasty
coronary artery bypass graft
revascularisation
stemi
ace inhibitor
Memorial University of Newfoundland
 (1.6 away) Contact site
  • 258 views
  • 21 Jan, 2021
  • +82 other locations